Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5867 Articles

Douglas A. McIntyre | Oct 1, 2008 at 6:59 AM EDT

UBS Taking Down Hospital Stocks (CYH, THC, UHS)

UBS has decided to downgrades the hospital sector this morning. It seems that perhaps not all medical and healthcare stocks…

Douglas A. McIntyre | Sep 29, 2008 at 7:21 AM EDT

Cardinal Health To Spin Off Med Tech (CAH)

Cardinal Health, Inc. (NYSE: CAH) is going to shuffle things up. The healthcare products and services company plans a tax-free…

Douglas A. McIntyre | Sep 25, 2008 at 2:28 PM EDT

Fluidigm IPO Shelved

It appears that the IPO market has lost another IPO. Fluidigm Corp. was set to come public. We had it…

Douglas A. McIntyre | Sep 24, 2008 at 5:52 PM EDT

Biotech Bonanza: Ligand Takes out Pharmacopeia (LGND, PCOP)

This might not be the biggest of biotech mergers out there, but deals are continuing in the bio-space. Ligand Pharmaceuticals…

Douglas A. McIntyre | Sep 23, 2008 at 11:07 AM EDT

Higher ImClone Bid Challenges Icahn At His Own Game (IMCL, BMY)

ImClone Systems Inc. (NASDAQ: IMCL) is among the biotech bonanza merger candidates with one deal on the table and perhaps…

Douglas A. McIntyre | Sep 17, 2008 at 8:03 AM EDT

Day Trader Alert: Gilead Sciences (GILD)

Gilead Sciences Inc. (NASDAQ: GILD) is trading down this morning. Goldman Sachs maintained its buy rating on the stock, but…

Douglas A. McIntyre | Sep 17, 2008 at 5:47 AM EDT

Abbott (ABT): A Resurrection Of The Stent Business

The stent business in the US has been dying and it is in trouble overseas. Stents are small mesh tubs…

Douglas A. McIntyre | Sep 15, 2008 at 9:26 AM EDT

Medarex & Bristol-Myers Show Positive Metastatic Melanoma Data (BMY, MEDX)

There is some very hopeful data out there this morning on cancer survival. Bristol-Myers Squibb Co. (NYSE: BMY) and Medarex,…

Douglas A. McIntyre | Sep 11, 2008 at 10:03 AM EDT

Bristol-Myers Re-Offers No New Offer for ImClone (IMCL, BMY)

Bristol-Myers Squibb (NYSE: BMY) has sent a letter to Imclone Systems (NASDAQ: IMCL) in response to yesterday’s rejection of its…

Douglas A. McIntyre | Sep 10, 2008 at 8:21 AM EDT

Day Trader Alert: ImClone Systems (IMCL, BMY)

ImClone Systems Inc. (NASDAQ: IMCL) is a biotech buyout bonanza stock that traders and investors have been watching closely. The…

Douglas A. McIntyre | Sep 9, 2008 at 9:35 AM EDT

Cardica Adding U.S. to E.U. & Japan Sales (CRDC)

A usually quiet Cardica, Inc. (NASDAQ: CRDC) is seeing a huge move in its stock today on strong upside volume. …

Douglas A. McIntyre | Sep 8, 2008 at 3:55 PM EDT

Biodel Trades Down Close To Net Asset Value (BIOD)

If you just read headlines on Biodel Inc. (Nasdaq: BIOD) this morning, you would have thought the news coming out…

Douglas A. McIntyre | Sep 2, 2008 at 8:11 AM EDT

More Blight For Merck (MRK)

Merck (MRK) and Schering-Plough (SGP) make two of the most widely sold drugs in the world. One is cholesterol drug…

Douglas A. McIntyre | Sep 1, 2008 at 11:26 AM EDT

Another Stent Failure For Boston Scientific (BSX)

Investors have another reason to bail out of Boston Scientific (BSX). It has been in a battle with the medical…

Douglas A. McIntyre | Aug 27, 2008 at 4:22 AM EDT

Eli Lilly’s (LLY) Gift To The Funeral Industry

The National Funeral Directors Association must be sending “thank you” cards to Eli Lilly (LLY) and it partner Amylin (AMLN).…

1 … 347 348 349 350 351 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

UBS Taking Down Hospital Stocks (CYH, THC, UHS)

Cardinal Health To Spin Off Med Tech (CAH)

Fluidigm IPO Shelved

Biotech Bonanza: Ligand Takes out Pharmacopeia (LGND, PCOP)

Higher ImClone Bid Challenges Icahn At His Own Game (IMCL, BMY)

Day Trader Alert: Gilead Sciences (GILD)

Abbott (ABT): A Resurrection Of The Stent Business

Medarex & Bristol-Myers Show Positive Metastatic Melanoma Data (BMY, MEDX)

Bristol-Myers Re-Offers No New Offer for ImClone (IMCL, BMY)

Day Trader Alert: ImClone Systems (IMCL, BMY)

Cardica Adding U.S. to E.U. & Japan Sales (CRDC)

Biodel Trades Down Close To Net Asset Value (BIOD)

More Blight For Merck (MRK)

Another Stent Failure For Boston Scientific (BSX)

Eli Lilly’s (LLY) Gift To The Funeral Industry

Here’s What a $500,000 Budget Actually Buys You in Naples, Florida

Dave Ramsey to a Debt-Free 50-Year-Old Who Left a $105K Job to Train Clients: You’re a Gym Rat That Gets Paid Sometimes

He Reached His Medicare Advantage Plan’s Out-of-Pocket Maximum. His Pharmacy Bills Kept Coming.

Here's What a $500,000 Budget Actually Buys You in Naples, Florida

Dave Ramsey to a Debt-Free 50-Year-Old Who Left a $105K Job to Train Clients: You're a Gym Rat That Gets Paid Sometimes

$10,000 in XRP vs $10,000 in HYPE: Which Is Worth More by 2030?

Here’s What a $500,000 Budget Actually Buys You in Naples, Florida

Health and Healthcare Articles

All Health and Healthcare Articles

UBS Taking Down Hospital Stocks (CYH, THC, UHS)

Cardinal Health To Spin Off Med Tech (CAH)

Fluidigm IPO Shelved

Biotech Bonanza: Ligand Takes out Pharmacopeia (LGND, PCOP)

Higher ImClone Bid Challenges Icahn At His Own Game (IMCL, BMY)

Day Trader Alert: Gilead Sciences (GILD)

Abbott (ABT): A Resurrection Of The Stent Business

Medarex & Bristol-Myers Show Positive Metastatic Melanoma Data (BMY, MEDX)

Bristol-Myers Re-Offers No New Offer for ImClone (IMCL, BMY)

Day Trader Alert: ImClone Systems (IMCL, BMY)

Cardica Adding U.S. to E.U. & Japan Sales (CRDC)

Biodel Trades Down Close To Net Asset Value (BIOD)

More Blight For Merck (MRK)

Another Stent Failure For Boston Scientific (BSX)

Eli Lilly’s (LLY) Gift To The Funeral Industry

Here’s What a $500,000 Budget Actually Buys You in Naples, Florida

Dave Ramsey to a Debt-Free 50-Year-Old Who Left a $105K Job to Train Clients: You’re a Gym Rat That Gets Paid Sometimes

He Reached His Medicare Advantage Plan’s Out-of-Pocket Maximum. His Pharmacy Bills Kept Coming.

Featured Reads

Here's What a $500,000 Budget Actually Buys You in Naples, Florida

Dave Ramsey to a Debt-Free 50-Year-Old Who Left a $105K Job to Train Clients: You're a Gym Rat That Gets Paid Sometimes